Trials / Recruiting
RecruitingNCT04529122
A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test
A Registry to Collect Characteristics and Outcomes From Patients With Solid Tumors Profiled With a Next-Generation Sequencing Test (WAYFIND-R)
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 15,000 (estimated)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
WAYFIND-R is a registry that aims to capture high-quality real-world data linking next-generation sequencing, treatments and outcomes from cancer patients diagnosed with a solid tumour. The WAYFIND-R has three main overarching objectives: 1. To provide a platform to support the design and conduct of clinical and epidemiological research; 2. To develop an evidence-generation platform to better understand health outcomes and cancer care processes; and 3. To characterize the treatments and clinical course of solid tumor cancers in patients who have undergone NGS testing.
Conditions
Timeline
- Start date
- 2020-08-27
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
- First posted
- 2020-08-27
- Last updated
- 2026-04-06
Locations
138 sites across 32 countries: Argentina, Austria, Brazil, Canada, Chile, Colombia, Egypt, Estonia, France, Germany, Greece, Hungary, India, Ireland, Israel, Lebanon, Mexico, Philippines, Poland, Portugal, Saudi Arabia, Serbia, Slovakia, Slovenia, South Africa, Spain, Taiwan, Thailand, Turkey (Türkiye), United Arab Emirates, United Kingdom, Vietnam
Source: ClinicalTrials.gov record NCT04529122. Inclusion in this directory is not an endorsement.